Loading clinical trials...
Loading clinical trials...
A Study of the Safety, Tolerability, Microbial Kinetics and Effect on Urinary Oxalate Excretion of FB-001 in Healthy Volunteers Fed a High Oxalate/Low Calcium Diet and in Patients With Enteric Hyperoxaluria
Conditions
Interventions
FB-001
Placebo
Locations
1
United States
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States
Start Date
November 16, 2022
Primary Completion Date
August 31, 2024
Completion Date
August 31, 2024
Last Updated
January 25, 2023
NCT06716502
NCT06290258
NCT00090662
NCT07310264
NCT07483606
NCT07310901
Lead Sponsor
Federation Bio Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions